XPO1 expression pancreas cancer prognosis survival

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
30 Apr 2019
Historique:
received: 01 04 2019
revised: 26 04 2019
accepted: 28 04 2019
entrez: 5 5 2019
pubmed: 6 5 2019
medline: 6 5 2019
Statut: epublish

Résumé

Pancreatic adenocarcinoma (PAC) is one of the most aggressive human cancers and new systemic therapies are urgently needed. Exportin-1 (XPO1), which is a member of the importin-β superfamily of karyopherins, is the major exporter of many tumor suppressor proteins that are involved in the progression of PAC. Promising pre-clinical data using XPO1 inhibitors have been reported in PAC, but very few data are available regarding XPO1 expression in clinical samples. Retrospectively, we analyzed

Identifiants

pubmed: 31052304
pii: jcm8050596
doi: 10.3390/jcm8050596
pmc: PMC6572621
pii:
doi:

Types de publication

Journal Article

Langues

eng

Déclaration de conflit d'intérêts

The authors have no conflict of interest to declare.

Références

J Pharmacol Sci. 2014;124(4):486-93
pubmed: 24739265
Oncotarget. 2014 Jun 15;5(11):3444-54
pubmed: 24899509
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
J Clin Oncol. 2016 Dec;34(34):4142-4150
pubmed: 26926685
Br J Cancer. 2014 Jul 15;111(2):281-91
pubmed: 24946002
PLoS One. 2015 Aug 06;10(8):e0133562
pubmed: 26247463
Nature. 2016 Mar 3;531(7592):47-52
pubmed: 26909576
Jpn J Cancer Res. 2000 Nov;91(11):1119-25
pubmed: 11092976
Oncol Rep. 2009 Jan;21(1):229-35
pubmed: 19082467
Cancer Res. 2017 Oct 15;77(20):5614-5627
pubmed: 28819023
Traffic. 2013 Oct;14(10):1042-52
pubmed: 23829533
Cancer Res. 2002 Feb 1;62(3):835-9
pubmed: 11830540
Cancer Lett. 2016 Dec 28;383(2):309-317
pubmed: 27693556
Oncotarget. 2018 Jul 20;9(56):30773-30786
pubmed: 30112106
Clin Invest Med. 2009 Dec 01;32(6):E315
pubmed: 20003838
Blood. 2012 Nov 29;120(23):4621-34
pubmed: 23034282
Oncotarget. 2016 Nov 29;7(48):78883-78895
pubmed: 27713151
BMC Med. 2017 Sep 20;15(1):170
pubmed: 28927421
Blood. 2011 Oct 6;118(14):3922-31
pubmed: 21841164
Br J Cancer. 1996 Aug;74(4):648-9
pubmed: 8761384
N Engl J Med. 2011 Feb 3;364(5):483-4; author reply 484-5
pubmed: 21288104
Mol Cancer Ther. 2015 Jul;14(7):1570-81
pubmed: 25934708
Mol Cancer Ther. 2017 Apr;16(4):717-728
pubmed: 27903750
BMC Cancer. 2015 Dec 01;15:941
pubmed: 26620414
Clin Cancer Res. 2013 Sep 15;19(18):4983-93
pubmed: 23918603
Bioorg Med Chem. 2008 Nov 1;16(21):9487-97
pubmed: 18835718
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Blood. 2017 Jun 15;129(24):3175-3183
pubmed: 28468797
PLoS One. 2012;7(2):e31507
pubmed: 22363658
PLoS Genet. 2008 May 23;4(5):e1000081
pubmed: 18535672
PLoS Med. 2010 Jul 13;7(7):e1000307
pubmed: 20644708
Nat Genet. 2015 Oct;47(10):1168-78
pubmed: 26343385
Cancer. 2008 Apr 15;112(8):1733-43
pubmed: 18306389
Am J Hematol. 2016 Nov;91(11):E478-E479
pubmed: 27468087
Science. 1996 Jan 19;271(5247):350-3
pubmed: 8553070
Oncotarget. 2018 Apr 20;9(30):21289-21295
pubmed: 29765539
Br J Cancer. 2005 Aug 22;93(4):387-91
pubmed: 16106245
Bioorg Med Chem. 2017 Aug 15;25(16):4444-4451
pubmed: 28689976
Mol Oncol. 2016 Oct;10(8):1169-82
pubmed: 27282075
Cell. 1988 May 20;53(4):549-54
pubmed: 2453289
Stat Med. 1990 Jul;9(7):811-8
pubmed: 2218183
Nature. 1997 Nov 20;390(6657):308-11
pubmed: 9384386
Oncol Rep. 2014 Aug;32(2):730-8
pubmed: 24898882
Int J Cancer. 2009 Apr 15;124(8):1829-40
pubmed: 19117056
J Surg Oncol. 2013 Jan;107(1):97-103
pubmed: 22991309
Med Oncol. 2013 Dec;30(4):726
pubmed: 24026662
Nat Med. 2011 Apr;17(4):500-3
pubmed: 21460848
Clin Cancer Res. 2017 Mar 15;23(6):1552-1563
pubmed: 27649553
Cancer Discov. 2014 May;4(5):527-37
pubmed: 24743138
Eur J Surg Oncol. 2012 Mar;38(3):245-51
pubmed: 22217907
Neurosurgery. 2009 Jul;65(1):153-9; discussion 159-60
pubmed: 19574837
Oncotarget. 2017 Jul 17;8(47):82144-82155
pubmed: 29137251
Genes (Basel). 2015 Mar 20;6(1):124-49
pubmed: 25802992
Leukemia. 2013 Jan;27(1):66-74
pubmed: 22847027
Cancer Cell. 2017 Aug 14;32(2):185-203.e13
pubmed: 28810144
Leukemia. 2014 Jan;28(1):155-65
pubmed: 23588715
Exp Cell Res. 1998 Aug 1;242(2):540-7
pubmed: 9683540
J Exp Clin Cancer Res. 2012 Aug 27;31:68
pubmed: 22925330
Clin Cancer Res. 2015 Oct 15;21(20):4508-13
pubmed: 26324742
Genes Chromosomes Cancer. 2011 Jun;50(6):456-65
pubmed: 21412932
Am J Hematol. 2016 Sep;91(9):923-30
pubmed: 27312795
Stat Appl Genet Mol Biol. 2004;3:Article3
pubmed: 16646809
Gastroenterology. 2013 Feb;144(2):447-456
pubmed: 23089203
Blood. 2013 May 16;121(20):4166-74
pubmed: 23564911
Cancer Biol Ther. 2015;16(7):1110-8
pubmed: 25996664
Science. 2008 Sep 26;321(5897):1801-6
pubmed: 18772397
Oncotarget. 2016 Mar 29;7(13):16581-92
pubmed: 26918731
J Hematol Oncol. 2014 Oct 04;7:67
pubmed: 25281264

Auteurs

David Jérémie Birnbaum (DJ)

Laboratoire d'Oncologie Prédictive, Centre de Recherche en Cancérologie de Marseille, Aix-Marseille Université, INSERM UMR1068, CNRS UMR725, F-13273 Marseille, France. david.birnbaum10@gmail.com.
Département d'Oncologie Médicale, Institut Paoli-Calmettes, F-13273 Marseille, France. david.birnbaum10@gmail.com.
Département de Chirurgie Générale et Viscérale, AP-HM, F-13000 Marseille, France. david.birnbaum10@gmail.com.

Pascal Finetti (P)

Laboratoire d'Oncologie Prédictive, Centre de Recherche en Cancérologie de Marseille, Aix-Marseille Université, INSERM UMR1068, CNRS UMR725, F-13273 Marseille, France. finettip@ipc.unicancer.fr.

Daniel Birnbaum (D)

Laboratoire d'Oncologie Prédictive, Centre de Recherche en Cancérologie de Marseille, Aix-Marseille Université, INSERM UMR1068, CNRS UMR725, F-13273 Marseille, France. daniel.birnbaum@inserm.fr.

Emilie Mamessier (E)

Laboratoire d'Oncologie Prédictive, Centre de Recherche en Cancérologie de Marseille, Aix-Marseille Université, INSERM UMR1068, CNRS UMR725, F-13273 Marseille, France. emilie.mamessier@inserm.fr.

François Bertucci (F)

Laboratoire d'Oncologie Prédictive, Centre de Recherche en Cancérologie de Marseille, Aix-Marseille Université, INSERM UMR1068, CNRS UMR725, F-13273 Marseille, France. bertuccif@ipc.unicancer.fr.
Département d'Oncologie Médicale, Institut Paoli-Calmettes, F-13273 Marseille, France. bertuccif@ipc.unicancer.fr.

Classifications MeSH